Table 3.

In vitro susceptibilities of bloodstream isolates of various species of Candida tested against BMS-207147 and itraconazole and stratified by fluconazole susceptibility category

Species and fluconazole susceptibility category (no. of isolates tested)aMIC (μg/ml)
BMS-207147Itraconazole
Range50%b90%cRange50%90%
C. albicans
 S (334)0.007–1.00.0070.030.007–1.00.030.12
 S-DD (1)2.0 2.02.04.0 4.04.0
 R (3)0.06–1616161.0–161616
 All (338)0.007–160.0070.030.007–160.030.12
C. glabrata
 S (66)0.015–2.00.250.50.06–2.00.251.0
 S-DD (34)0.007–8.00.51.00.25–161.02.0
 R (6)0.5–8.04.08.02.0–161616
 All (106)0.007–8.00.251.00.06–160.52.0
C. parapsilosis, S (97)0.007–0.120.030.060.015–0.50.120.25
C. tropicalis, S (49)0.007–0.50.030.120.015–1.00.120.25
C. krusei
 S (1)0.250.250.250.120.120.12
 S-DD (7)0.06–2.00.252.00.12–1.00.51.0
 R (2)0.25–0.50.250.52.0 2.02.0
 All (10)0.06–2.00.250.50.12–2.00.52.0
C. guilliemondii, S (10)0.03–2.00.120.250.12–1.00.251.0
C. lusitaniae, S (2)0.015–0.030.0150.030.06–0.250.060.25
All Candida spp.
 S (559)0.007–2.00.0150.120.007–2.00.060.5
 S-DD (42)0.007–8.00.51.00.12–161.02.0
 R (11)0.06–164.0161.0–161616
 All (613)0.007–160.0150.250.007–160.060.5
  • a Fluconazole susceptibility categories according to NCCLS M27-A (7): S, ≤8.0 μg/ml; S-DD, 16 to 32 μg/ml; R, ≥64 μg/ml.

  • b 50%, MIC50.

  • c 90%, MIC90.